在 #ESMO26，@AndreaNecchi 讨论了一项关于肌层浸润性膀胱癌新辅助化疗联合或不联合 nivolumab 的 III 期试验、GDFather-NEO 的结果，以及 GU 鳞状细胞癌的治疗。
http://VJOncology.com 上还有更多内容 👀
@myESMO #BladderCancer #GUSM
50 浏览 · 1 赞 · 0 转发 · 0 回复
Emotional distress (ED) upfront neoadjuvant ipilimumab + nivolumab (IPI+NIVO) is associated with lower pathological response and toxicity
https://esmocongress.esmo.orgResults from a phase 3 trial of neoadjuvant (neoadj) chemotherapy alone vs in combination with nivolumab followed by postsurgical adjuvant nivolumab in patients (pts) with muscle-invasive bladder cancer (MIBC)
https://esmocongress.esmo.orgFinal pathological and radiological outcomes and initial EFS from a blinded, exploratory phase 2 trial of nivolumab ± visugromab in MIBC (GDFather-NEO)
https://esmocongress.esmo.orgPrimary analysis of HBI-8000-303: A randomized phase 3 trial of nivolumab plus HBI-8000 or placebo in advanced melanoma
https://esmocongress.esmo.org- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
https://esmocongress.esmo.org来源：VJ Oncology · x.com